Neurocrine Biosciences INC 8-K filings

Neurocrine Biosciences files an 8-K/A amendment to include audited and unaudited financial statements for Soleno Therapeutics and pro forma combined financial information following the acquisition.

Neurocrine Biosciences reported a 39% year-over-year revenue increase to $959 million for Q2 2026, driven by strong sales of INGREZZA and CRENESITY, and raised full-year INGREZZA guidance.

Neurocrine Biosciences stockholders approved the amendment of the 2025 Equity Incentive Plan and re-elected three Class III directors at the 2026 Annual Meeting.

Neurocrine Biosciences has finalized its acquisition of Soleno Therapeutics, adding VYKAT XR for Prader-Willi syndrome to its rare disease portfolio.

Neurocrine Biosciences reported a 44% year-over-year increase in Q1 2026 net product sales to $811 million, driven by INGREZZA and CRENESSITY, and announced a $2.9 billion acquisition of Soleno Therapeutics.

Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash to expand its rare disease and endocrinology portfolio.

Neurocrine Biosciences announced robust fourth-quarter and full-year 2025 financial results, driven by strong product sales, and provided 2026 financial expectations.

Neurocrine Biosciences, Inc. has extended the employment agreement for Dr. Eiry W. Roberts as Strategic Advisor through December 31, 2026.

Neurocrine Biosciences announced robust third-quarter 2025 financial results, driven by significant year-over-year growth in total net product sales and strong performance from INGREZZA and CRENESSITY.

Neurocrine Biosciences announced robust second-quarter 2025 financial results, driven by strong INGREZZA and CRENESSITY sales, while narrowing its full-year INGREZZA sales guidance.

Neurocrine Biosciences, Inc. announced the formalization of its Chief Medical Officer transition, with Dr. Eiry W. Roberts moving to a strategic advisory role through December 31, 2025, maintaining her current compensation and severance benefits.

Neurocrine Biosciences held its 2025 Annual Meeting of Stockholders, approving key proposals including the 2025 Equity Incentive Plan and an amendment to the Employee Stock Purchase Plan.

Neurocrine Biosciences announces first quarter 2025 financial results, including INGREZZA net product sales of $545 million, and reaffirms its 2025 financial guidance.

Neurocrine Biosciences has appointed Dr. Sanjay Keswani as its new Chief Medical Officer, effective June 2, 2025, succeeding Dr. Eiry W. Roberts, who will transition to a strategic advisory role.

Neurocrine Biosciences announces positive Q4 and full-year 2024 financial results, driven by INGREZZA sales, and provides a promising financial outlook for 2025, including the launch of CRENESSITY.

Neurocrine Biosciences amends its agreement with Takeda, securing exclusive worldwide rights to develop and commercialize osavampator, a potential treatment for major depressive disorder, excluding Japan.

Neurocrine Biosciences has announced the commercial availability of CRENESSITY in the U.S. for the treatment of classic congenital adrenal hyperplasia.

Neurocrine Biosciences has entered into an accelerated share repurchase agreement with Goldman Sachs to buy back $300 million of its common stock.

Neurocrine Biosciences announced strong third-quarter 2024 financial results, highlighted by a 26% year-over-year increase in INGREZZA sales, and raised its full-year sales guidance while also authorizing a $300 million share repurchase program.

Neurocrine Biosciences has appointed Kyle Gano as President and CEO, effective October 11, 2024, and has entered into an amended employment agreement with him.

Neurocrine Biosciences reports positive top-line data from its Phase 2 clinical trial of NBI-1117568, a novel schizophrenia treatment, showing significant symptom reduction and good tolerability.

Neurocrine Biosciences announced positive second quarter 2024 financial results, highlighted by a 32% year-over-year growth in INGREZZA sales, and raised its full-year sales guidance for the drug.

Neurocrine Biosciences has announced the retirement of its CEO, Kevin C. Gorman, Ph.D., and the appointment of Kyle Gano, Ph.D., as his successor, effective October 11, 2024.

Neurocrine Biosciences held its 2024 Annual Meeting, electing four Class I directors, approving executive compensation on an advisory basis, and ratifying the appointment of Ernst & Young LLP as its independent auditor.

Neurocrine Biosciences announced a successful first quarter of 2024, highlighted by a 23% year-over-year increase in INGREZZA sales and positive clinical trial results.

Neurocrine Biosciences announced robust financial results for 2023, driven by strong sales of INGREZZA, and provided positive financial guidance for 2024.